Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Labetalol Clear all
Completed Phase 4 Interventional Results available

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

NCT01114971
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Fentanyl, Labetalol, Esmolol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department

NCT00765648
View directory record Official record
Conditions
Hypertensive Urgency
Interventions
nicardipine intravenous, Labetalol
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 4 Interventional

Acute Labetalol Use in Preeclampsia

NCT03872336
View directory record Official record
Conditions
Preeclampsia With Severe Features
Interventions
Experimental labetalol dose, Current standard of care
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment Targets for Chronic Hypertension in Pregnancy

NCT00194974
View directory record Official record
Conditions
Pregnancy Toxemia, Hypertension, Proteinuria
Interventions
methyldopa, labetalol, nifedipine, clonidine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Not applicable Interventional Results available

Oral Nifedipine Versus Oral Labetalol

NCT02168309
View directory record Official record
Conditions
Severe Postpartum Hypertension
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 4 Interventional

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

NCT05019027
View directory record Official record
Conditions
Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional

Effects of Labetalol on Nicotine Administration in Humans - 14

NCT00000297
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Labetalol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Phase 3 Interventional

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

NCT05551104
View directory record Official record
Conditions
Postpartum Complication, Maternal Hypertension, High Blood Pressure
Interventions
Oral Nifedipine, Oral Labetalol
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Not listed Early Phase 1 Interventional

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

NCT03105661
View directory record Official record
Conditions
Obesity, Morbid, Preeclampsia
Interventions
Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Elevated Blood Pressures in Early Pregnancy

NCT05955040
View directory record Official record
Conditions
Elevated Blood Pressure, Pregnancy Induced Hypertension
Interventions
Nifedipine, Labetalol
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Phase 4 Interventional

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

NCT06915792
View directory record Official record
Conditions
Postpartum Hypertension (PPHT)
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Not applicable Interventional

Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study

NCT07363343
View directory record Official record
Conditions
Hypertension, Postpartum Preeclampsia
Interventions
Nifedipine and Enalapril, Nifedipine and Labetalol
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Phase 4 Interventional

A Preliminary Study for INFORMED

NCT05585125
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 4 Interventional Results available

Impact of Beta-blockers on Physical Function in HFpEF

NCT04767061
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 17, 2026, 3:00 AM EDT
Enrolling by invitation Not applicable Interventional

Comparison of Post-Craniotomy Blood Pressure Targets

NCT07093151
View directory record Official record
Conditions
Intracranial Hemorrhage, Hypertensive, Craniotomy Tumor Removal Surgery
Interventions
Target SBP <160mmHg, Target SBP <140 mmHg
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Phase 4 Interventional

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

NCT05309460
View directory record Official record
Conditions
Postpartum Preeclampsia, Hypertension in Pregnancy
Interventions
Labetalol Oral Tablet, NIFEdipine ER
Drug
Lead sponsor
Nebraska Methodist Health System
Other
Eligibility
19 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project

NCT05989581
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Labetalol or Nifedipine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 89 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 4 Interventional Results available

Postpartum Hypertension Study

NCT05139238
View directory record Official record
Conditions
Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Pregnancy-Induced Hypertension in Postpartum, Hypertensive Emergency
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional

Effects of Labetalol on Human Cocaine Use - 8

NCT00000291
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Labetalol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
20 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 3:00 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial

NCT00293735
View directory record Official record
Conditions
Preeclampsia, Pregnancy Induced Hypertension, Gestational Hypertension, Chronic Hypertension, Superimposed Preeclampsia
Interventions
labetalol (seizure prevention), MgSO4 (seizure prevention)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
15 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional Results available

Esmolol vs. Labetalol in Endoscopic Sinus Surgery

NCT03661346
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Labetalol, Esmolol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 17, 2026, 3:00 AM EDT